BioXcel Unveils Next-Generation Big Data Analytics Platform: PharmGPS(TM) 2.0
Engine Provides Unparalleled Drug Discovery, Development and Performance Benchmarking Capabilities
BRANFORD, Conn., Oct. 7, 2015 (GLOBE NEWSWIRE) -- BioXcel Corporation, a global leader in cloud-based big data platforms and developer of transformative patient treatments, today announced the launch of the latest version of its cloud-based pharma big data analytics platform - PharmGPS™ 2.0. This proprietary platform integrates BioXcel's ApolloTRIM discovery engine with its PharmGPSTM Decision Genius platform, providing recursive-mapping capabilities for drug discovery and predictive analytics. The inherent nature of the platform is highly disruptive. It is able to rapidly generate therapeutic area galactic maps for any disease and apply network-based pharmacology to uncover novel pharmaceutical product opportunities. The platform has in-built predictive and cognitive capabilities capable of addressing the complex decision making needs of the pharmaceutical and biotechnology industry.
The company's President and Chief Scientific Officer, Krishnan Nandabalan and VP, Oncology R&D, Luca Rastelli will be showcasing the power of the PharmGPS™ Platform in their joint presentation titled 'Big Data to Clinical Leads' at Phacilitate's Big Data in Clinical Development conference in Washington D.C on October 7th- 8th.
PharmGPS™ 2.0 enables the comprehensive assessment of both structured and unstructured data to generate actionable results across all major therapeutic areas. By providing "pan-therapeutic area" access and analyses, PharmGPS™ 2.0 allows users to accurately map the biological connections and relationships between diseases, drugs and MOAs to identify drug candidates. In addition, the platform offers a responsive, intuitive and attractive interface with a variety of tools, customizable features and high definition graphics. These attributes enable multiple scenario analyses related to disease prioritization, clinical and preclinical performance benchmarking, projected market performance and portfolio optimization. The platform has resulted in the development and expansion of the Company's portfolio across multiple therapeutic areas.
"We are thrilled to launch this unique and highly interactive pharma big data analytics platform that is centered on fostering innovation by leveraging the capabilities of our Big Data Innovation Lab to address the industry challenges in addressing unmet patient needs. Our proprietary suite of algorithms has a profound impact on the productivity of the biopharma pipeline at-large and our internal portfolio of clinical programs," said BioXcel's President and Chief Scientific Officer, Krishnan Nandabalan, Ph.D.
A live and dynamic cloud-based pharma big data analytics platform, BioXcel's proprietary PharmGPS™ Decision Genius platform revolutionizes decision making by helping clients gain live intelligence on treatment paradigms, product opportunities, key market movers, product blueprints, portfolio impact and commercial launch scenarios. The suite's cognitive insights help identify potential market winners and streamline internal and external innovation, enabling better R&D prioritization and justifying sound investment decisions. Powered by an intuitive and interactive user interface that enables first mover advantage, predictive simulation, risk mitigation and operational excellence, the platform addresses all major therapeutic areas with a dedicated focus on immuno-oncology and orphan diseases. The platform utilizes complex analyses, such as combination strategies using immuno-oncology agents relevant to specific tumors and patient segments to obtain actionable insights. This cutting-edge, high density content platform is capable of handling large volumes of unstructured, multi-dimensional pharma data. The platform implements high levels of transparency to enable rational decision making by simplifying the exploration and analysis of unstructured pharmaceutical data as well as defining queries. Hosted in the cloud, its multi-tenancy design yields significant cost and time benefits, while being instantly scalable and flexible.
BioXcel is a global leader in providing cloud-based Pharma big data solutions for the discovery of novel therapeutic products and the performance benchmarking of pipeline innovation and marketed products in all major therapeutic areas. Our first in class Big Data Innovation Lab is focused on the development of transformative patient treatments for strategic portfolio growth and leverages; PharmGPS™ - a live analytics platform; an Integrated Center of Xcellence housing multidisciplinary scientific, commercial and medical teams; and an executive team that offers deep domain expertise. Committed to innovation, product excellence and partner success, BioXcel's global collaborations span the biopharmaceutical ecosystem. We are headquartered in Branford, CT, USA with operations in Asia.
CONTACT: BioXcel Corporation Anita Ganjoo Corporate Communications Email: firstname.lastname@example.org Tel: 203 273 8388 The Ruth Group for BioXcel Lee Roth (Investors) Email: email@example.com Tel: 646 536 7012Source: BioXcel Corporation
Released October 7, 2015